Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sertraline
Drug ID BADD_D02010
Description Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
Indications and Usage Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD).[L9016] Common off-label uses for sertraline include the prevention of post stroke depression[A187078], generalized anxiety disorder (GAD), fibromyalgia, premature ejaculation, migraine prophylaxis, diabetic neuropathy, and neurocardiogenic syncope.[L5227]
Marketing Status approved
ATC Code N06AB06
DrugBank ID DB01104
KEGG ID D02360
MeSH ID D020280
PubChem ID 68617
TTD Drug ID D0K0TC
NDC Product Code 76282-214; 23155-759; 68180-353; 55700-225; 63187-055; 70518-0153; 70518-1461; 70518-1617; 71335-9714; 0615-7990; 65427-009; 55154-3570; 0615-7991; 76282-212; 0904-6924; 50090-5848; 70518-1040; 23155-757; 70518-2512; 0904-6925; 68180-351; 68180-352; 68071-4400; 63187-212; 68788-7329; 0615-7989; 0904-6926; 55154-3569; 63187-478; 67296-1199; 70934-958; 76282-213; 23155-758; 50090-0989
UNII QUC7NX6WMB
Synonyms Sertraline | Zoloft | Altruline | Lustral | Apo-Sertraline | Apo Sertraline | Aremis | Besitran | Sealdin | Gladem | Novo-Sertraline | Novo Sertraline | ratio-Sertraline | ratio Sertraline | Rhoxal-sertraline | Rhoxal sertraline | Sertraline Hydrochloride | Hydrochloride, Sertraline | Sertraline Hydrochloride (1S-cis)-Isomer | Gen-Sertraline | Gen Sertraline
Chemical Information
Molecular Formula C17H17Cl2N
CAS Registry Number 79617-96-2
SMILES CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Throat irritation22.12.03.029; 07.05.05.0370.000224%Not Available
Throat tightness22.12.03.031; 19.01.02.0050.000098%Not Available
Thrombocytopenia01.08.01.002--Not Available
Thyroiditis05.02.04.0010.000057%Not Available
Tic19.11.04.001; 17.02.05.0240.000313%Not Available
Tinnitus17.04.07.004; 04.04.01.0020.000368%
Tongue blistering07.14.02.0140.000013%Not Available
Tongue disorder07.14.01.0020.000034%Not Available
Tongue oedema07.14.02.007; 23.04.01.009; 10.01.05.0080.000045%Not Available
Tongue spasm07.14.02.0080.000038%Not Available
Tongue ulceration07.14.01.003--Not Available
Tonsillar hypertrophy22.04.05.0060.000013%Not Available
Tooth loss12.01.17.026; 07.09.09.0010.000019%Not Available
Torsade de pointes02.03.04.0050.000083%Not Available
Torticollis17.01.03.003; 15.05.04.0030.000187%Not Available
Toxic epidermal necrolysis23.03.01.008; 12.03.01.015; 11.07.01.006; 10.01.01.0060.000070%
Tremor17.01.06.0020.002696%
Tricuspid valve incompetence02.07.05.0010.000166%Not Available
Trismus17.01.03.004; 15.05.04.0040.000357%
Tunnel vision17.17.01.013; 06.02.07.0050.000057%Not Available
Upper gastrointestinal haemorrhage24.07.02.024; 07.12.02.0060.000083%
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urge incontinence20.02.02.0080.000013%Not Available
Urinary hesitation20.02.02.0090.000045%Not Available
Urinary incontinence20.02.02.010; 17.05.01.0080.000257%
Urinary retention20.02.02.0110.000408%
Urinary tract disorder20.08.01.0010.000028%Not Available
Urine abnormality20.02.01.0130.000025%Not Available
Urticaria23.04.02.001; 10.01.06.001--
Vaginal discharge21.08.02.002--
The 22th Page    First    Pre   22 23 24 25 26    Next   Last    Total 36 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene